These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38164804)

  • 1. Utility of peak inspiratory flow measurement for dry powder inhaler use in chronic obstructive pulmonary disease.
    Loh CH; Ohar JA
    Curr Opin Pulm Med; 2024 Mar; 30(2):174-178. PubMed ID: 38164804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease.
    Ohar JA; Ferguson GT; Mahler DA; Drummond MB; Dhand R; Pleasants RA; Anzueto A; Halpin DMG; Price DB; Drescher GS; Hoy HM; Haughney J; Hess MW; Usmani OS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():79-92. PubMed ID: 35023914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chinese expert consensus on standardized inhaler device application in stable chronic airway diseases (2023)].
    Inhalation Therapy and Respiratory Rehabilitation Group, Respiratory Equipment Committee of China Association of Medical Equipment
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1055-1067. PubMed ID: 37914418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inspiratory Flow Parameters Through Dry Powder Inhalers in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD): Device Resistance Does Not Limit Use in COPD.
    Jõgi R; Mattila L; Vahteristo M; Takala A; Lähelmä S; Vartiainen VA; Lindqvist A
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1193-1201. PubMed ID: 33958863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.
    Altman P; Wehbe L; Dederichs J; Guerin T; Ament B; Moronta MC; Pino AV; Goyal P
    BMC Pulm Med; 2018 Jun; 18(1):100. PubMed ID: 29898702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung characteristics in elderly males and females patients with COPD: differences and optimal use of dry powder inhalers (DPIs).
    Terzano C; Oriolo F
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2708-2716. PubMed ID: 28678314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical recommendations for dry powder inhaler use in the management of COPD in primary care.
    Leving MT; Bosnic-Anticevich S; van Cooten J; de Sousa JC; Cvetkovski B; Dekhuijzen R; Dijk L; Pardo MG; Gardev A; Gawlik R; van der Ham I; Janse Y; Lavorini F; Maricoto T; Meijer J; Metz B; Price D; Roman-Rodriguez M; Schuttel K; Stoker N; Tsiligianni I; Usmani O; Emerson-Stadler R; Kocks JWH
    NPJ Prim Care Respir Med; 2022 Dec; 32(1):59. PubMed ID: 36575175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Implications of Peak Inspiratory Flow in COPD: Post Hoc Analyses of the TRONARTO Study.
    Mahler DA; Watz H; Emerson-Stadler R; Ritz J; Gardev A; Shaikh A; Drummond MB
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1729-1740. PubMed ID: 37599896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Evaluation of Exacerbations Associated with Suboptimal Peak Inspiratory Flow Among Stable Outpatients with COPD.
    Mahler DA; Niu X; Deering KL; Dembek C
    Int J Chron Obstruct Pulmon Dis; 2022; 17():559-568. PubMed ID: 35313719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Hamilton M; Anderson M; Dhand R; Patmore O; Prime D; Taylor E
    J Aerosol Med Pulm Drug Deliv; 2023 Feb; 36(1):34-43. PubMed ID: 36695722
    [No Abstract]   [Full Text] [Related]  

  • 12. High Prevalence of Suboptimal Peak Inspiratory Flow in Hospitalized Patients With COPD: A Real-world Study.
    Mahler DA; Demirel S; Hollander R; Gopalan G; Shaikh A; Mahle CD; Elder J; Morrison C
    Chronic Obstr Pulm Dis; 2022 Jul; 9(3):427-438. PubMed ID: 35788259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological predictors Of peak inspiRatory flow using Observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation.
    Price DB; Yang S; Ming SWY; Hardjojo A; Cabrera C; Papaioannou AI; Loukides S; Kritikos V; Bosnic-Anticevich SZ; Carter V; Dorinsky PM
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3937-3946. PubMed ID: 30587952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.
    Malmberg LP; Rytilä P; Happonen P; Haahtela T
    Int J Chron Obstruct Pulmon Dis; 2010 Aug; 5():257-62. PubMed ID: 20714380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhalation characteristics of patients when they use different dry powder inhalers.
    Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
    J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suboptimal Peak Inspiratory Flow and Critical Inhalation Errors are Associated with Higher COPD-Related Healthcare Costs.
    Leving MT; van Boven JFM; Bosnic-Anticevich SZ; van Cooten J; Correia de Sousa J; Cvetkovski B; Dekhuijzen R; Dijk L; García Pardo M; Gardev A; Gawlik R; van der Ham I; Hartgers-Gubbels ES; Janse Y; Lavorini F; Maricoto T; Meijer J; Metz B; Price DB; Roman-Rodríguez M; Schuttel K; Stoker N; Tsiligianni I; Usmani OS; Kocks JH
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2401-2415. PubMed ID: 36185173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD.
    Chetta A; Yorgancioglu A; Scuri M; Barile S; Guastalla D; Dekhuijzen PNR
    BMC Pulm Med; 2021 Feb; 21(1):65. PubMed ID: 33632183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The variability of peak inspiratory flow (PIF) on valves imitating dry powder inhalers resistance during asthma and COPD exacerbations].
    Grabowski M; Barg W; Chmielowicz B; Kopeć A; Panaszek B
    Pneumonol Alergol Pol; 2007; 75(4):324-30. PubMed ID: 18080981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
    Bagherisadeghi G; Chrystyn H; Abadelah M; Larhrib EH
    Eur J Pharm Sci; 2019 Nov; 139():105059. PubMed ID: 31472254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.